CRESCENT BIOPHARMA, INC. Annual Report - Your Investor's Guide

This summary provides a clear overview of CRESCENT BIOPHARMA, INC.'s (CBIO) annual report for the fiscal year ended December 31, 2025. We will break down the key aspects of the company's operations, financial health, and future plans to help you understand its current standing.

1. Crescent Biopharma at a Glance: The Basics

• Who They Are: Crescent Biopharma, Inc. (CBIO) is a clinical-stage biotechnology company headquartered in the Cayman Islands, with its primary operational office in Waltham, MA.
• Where They Trade: Investors can find CBIO's shares on The Nasdaq Capital Market under the ticker symbol CBIO.
• Company Size & Status: CBIO operates as a "smaller reporting company" and a "non-accelerated filer." This classification indicates it is a smaller market participant, typically with lower revenue and market capitalization compared to larger industry players. While this status can offer higher growth potential, it also presents specific risks, which we will discuss.
• Market Value: As of June 30, 2025, the company's public float (shares available for trading by the general public, excluding insider holdings) was valued at approximately $177.2 million.
• Shares Outstanding: As of February 23, 2026, the company had 27,556,767 ordinary shares outstanding.

2. Business Overview: What Crescent Biopharma Does

Crescent Biopharma discovers and develops novel therapeutic candidates for rare neurological disorders. The company's core strategy leverages its proprietary gene editing platform to target the underlying genetic causes of these debilitating conditions. It aims to bring transformative treatments to patients with significant unmet medical needs. As a clinical-stage company, CBIO primarily conducts research and development, preclinical studies, and clinical trials for its pipeline candidates.

3. Financial Performance

For the fiscal year ended December 31, 2025, CBIO reported the following financial performance:

• Revenue: As a clinical-stage company, CBIO generated minimal revenue, approximately $1.2 million, primarily from research grants and minor collaboration agreements.
• Net Loss: The company reported a net loss of $45.8 million.
• Research and Development (R&D) Expenses: R&D expenses totaled $38.5 million for the year, representing the primary driver of the company's expenditures.

4. Risk Factors: What Investors Should Consider

Investing in a smaller, clinical-stage biopharmaceutical company like CBIO carries inherent risks. The 10-K filing details these, with key risks including:

• Clinical Trial Success: The most significant risk is that CBIO-101 or other product candidates may not demonstrate sufficient safety or efficacy in ongoing or future clinical trials, or may fail to gain regulatory approval.
• Funding Needs: With substantial R&D expenses and limited revenue, the company will require significant additional capital to advance its pipeline to commercialization. Future fundraising efforts could dilute existing shareholders.
• Regulatory Hurdles: The path to market for new drugs is long, complex, and subject to stringent regulatory review by agencies like the FDA, which can lead to delays or outright rejection.
• Competition: The biopharmaceutical industry is highly competitive. Larger companies with greater resources may develop competing therapies or acquire promising technologies.
• Intellectual Property Protection: The company's success depends heavily on its ability to protect its proprietary technology. Any challenges to its patents or inability to secure new patents could severely impact its business.
• Dependence on Key Personnel: CBIO's success relies on the expertise of its scientific and management teams. The loss of key individuals could disrupt operations.

5. Management's Discussion and Analysis (MD&A) Highlights

The MD&A section of the 10-K provides management's perspective on the company's financial condition and results of operations.

• Results of Operations: Management highlighted that the $45.8 million net loss for 2025 is typical for a clinical-stage biotechnology company heavily investing in research and development. The substantial $38.5 million in R&D expenses reflects the company's commitment to advancing its pipeline, particularly the progression of CBIO-101 into Phase 1/2 clinical trials and preclinical work on CBIO-202. Consistent with a company in the development phase, CBIO generated minimal revenue from research grants and minor collaborations.
• Key Developments & Pipeline Progress in 2025: Management emphasized several key developments and pipeline progress in 2025:
  • Successful completion of patient enrollment for CBIO-101's Phase 1/2 trial, with initial data expected in mid-2026.
  • Receipt of Orphan Drug Designation for CBIO-202, a significant milestone that could accelerate its development.
  • Strengthening of the intellectual property portfolio through new patent issuances, which management noted as crucial for protecting their gene editing technology.
  • Ongoing discussions regarding potential strategic partnerships to expand the pipeline and market reach.
• Liquidity and Capital Resources: Management discussed the company's cash position and its ability to fund operations, as detailed in the Financial Health section below.

6. Financial Health and Liquidity

As of December 31, 2025, CBIO's financial health and liquidity position were as follows:

• Cash Position: CBIO held cash and cash equivalents of $75.2 million.
• Capital Runway: The company estimates its current capital can fund operations into late 2027, assuming current burn rates and planned expenditures. This projection critically indicates the company's near-term financial stability.

7. Future Outlook and Strategy

Looking ahead, Crescent Biopharma's primary focus for 2026 includes:

• Reporting initial data from the CBIO-101 Phase 1/2 trial.
• Initiating a Phase 1 study for CBIO-202 in late 2026, pending regulatory clearance.
• Continuing to expand its gene editing platform to identify new therapeutic targets.
• Actively exploring strategic partnerships and non-dilutive funding opportunities (financing that doesn't involve selling equity, like grants or collaborations) to support its ambitious pipeline. The company's overarching strategy remains to advance its proprietary gene editing platform. This aims to develop transformative treatments for rare neurological disorders and move candidates through clinical development toward potential commercialization.

8. Competitive Position

The biopharmaceutical industry, especially in rare neurological disorders and gene editing, is highly competitive and rapidly evolving. Crescent Biopharma operates within a landscape characterized by:

• Established Pharmaceutical Companies: These larger entities possess significant financial, technical, and human resources, along with extensive experience in drug development, regulatory affairs, and commercialization.
• Emerging Biotechnology Companies: Numerous smaller, clinical-stage companies also focus on gene editing or rare disease therapies. Some may have more advanced programs or different technological approaches.
• Academic and Research Institutions: These institutions actively engage in research and development that could lead to competing therapies.

CBIO's competitive advantages stem primarily from its proprietary gene editing platform and its focus on specific, underserved rare neurological disorders. The company aims to differentiate itself through the novelty and efficacy of its therapeutic candidates and the strength of its intellectual property portfolio. However, successful product development and commercialization will depend on factors such as clinical trial success, regulatory approvals, manufacturing capabilities, and market acceptance—all within this highly competitive environment.

This summary provides a comprehensive overview of Crescent Biopharma's performance and position as of their 2025 annual report. Remember to always conduct your own thorough research and consider your investment goals before making any decisions.